Key result
Genetically or pharmacologically modulating myosin could alleviate muscle pathology in inherited cardiac and skeletal myopathies.
Why the study?
Does genetic or pharmacological modulation of myosin alleviate muscle pathology in inherited cardiac and skeletal myopathies?
Does genetic or pharmacological modulation of myosin alleviate muscle pathology in inherited cardiac and skeletal myopathies?
Modulating myosin represents a promising therapeutic strategy for inherited cardiac and skeletal myopathies that currently lack effective treatments.
Should not yet change practice in myopathies; leaves open myosin modulation for prospective trials.
The dysfunction in a number of inherited cardiac and skeletal myopathies is primarily due to an altered ability of myofilaments to generate force and motion. Despite this crucial knowledge, there are, currently, no effective therapeutic interventions for these diseases. In this short review, we discuss recent findings giving strong evidence that genetically or pharmacologically modulating one of the myofilament proteins, myosin, could alleviate the muscle pathology. This should constitute a research and clinical priority.
No takes yet. Share an insight, caveat, or question.
Ochala et al. (2016) conducted a review in Inherited cardiac and skeletal myopathies. Myosin modulation (genetic or pharmacological) was evaluated. Genetically or pharmacologically modulating myosin could alleviate muscle pathology in inherited cardiac and skeletal myopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: